AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 122 min read$CMND

HRT FINANCIAL LP sold $28K of CMND

HRT FINANCIAL LP sold 225,191 shares of Clearmind Medicine Inc. (CMND) at $0.12 on 2026-06-11.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jun 12, 2026, 8:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CMND
Neutral
medium confidence
Mentioned
$CMND
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMNDNeutralLow
01

Why it matters

The newest disclosed fact is the 10% owner’s open-market sale of 225,191 shares at $0.1230/share, leaving 1,838,075 shares post-transaction.

02

Market read

Traders may monitor CMND for incremental selling pressure after the filing, but the disclosure lacks any accompanying fundamental catalyst.

03

What to watch

For microcaps, insider sales can be mechanically driven by diversification/taxes; traders should check whether other insiders also sold around the same window and whether trading volume spikes after the filing.

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-12; sale dated 2026-06-11

Background

The article summarizes an SEC Form 4 insider transaction for Clearmind Medicine Inc. (CMND).

Company-level read

Ticker impact

$CMNDNeutralMedium confidence
Context

HRT Financial LP (10% owner) filed a Form 4 selling 225,191 CMND shares in an open-market transaction on 2026-06-11.

Expected impact

Likely limited, short-lived impact unless follow-on insider selling accelerates or volume/price action confirms a broader negative read.

Evidence & confidence

The filing is a primary insider-transaction disclosure, but the article provides no new fundamentals (no guidance, trial, deal, or regulatory event) and no 10b5-1 plan context.

Market effects

Sector

Minimal; this is company-specific insider selling with no sector-wide regulatory/clinical signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be routine liquidity management (and the absence of a stated 10b5-1 plan doesn’t prove opportunistic selling).

Key entities

  • issuer
    Clearmind Medicine Inc.

    CMND, the company whose shares were sold by a 10% owner.

  • insider
    HRT Financial LP

    10% owner who sold 225,191 shares via open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CMND insider trading history →

Related articles

SEP 1
$CMNDMedAI 8/10

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine (CMND) has started Phase IIa of its trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled. The trial is evaluating safety, tolerability, and preliminary efficacy. The company reported positive data from earlier trial phases, supporting continued development. CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic.

sina.com.hk2 min
AUG 13
$CMNDMed

Clearmind Medicine Inc.: Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

Clearmind Medicine (Nasdaq: CMND) said its independent DSMB approved advancing its FDA-regulated Phase I/II trial of CMND-100 for alcohol use disorder from Part A to Parts B and C. Part A met the primary safety endpoint in healthy participants. Part B will test 80 mg and 160 mg in AUD patients; Part C will test 160 mg in healthy participants.

finanznachrichten.de4 min
AUG 7
$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

rttnews.com7 min
MAY 29
$CMNDMedAI 9/10

Clearmind Medicine Shares Jump 47% After Japan Patent Filing For Depression Treatment

Clearmind Medicine Inc. (CMND) shares rose 46.72% to $3.59 on Friday after the company said a Japanese patent application was published covering compositions using 5-Methoxy-2-aminoindan (MEAI) for depression treatment. The filing, the company said, adds to its intellectual property portfolio for non-hallucinogenic neuroplastogen-derived therapeutics. Volume was 41.05 million shares versus 612,955 average.

rttnews.com3 min